CompletedPhase 2NCT02716272
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Principal Investigator
- Arnaud Scherpereel, MD, PhD, M.D., Ph.DIntergroupe Francophone de Cancerologie Thoracique
- Intervention
- Nivolumab(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2019
Study locations (22)
- Angers - CHU, Angers, France
- Avignon - Institut Sainte-Catherine, Avignon, France
- CHU, Clermont-Ferrand, France
- Dijon - CHU, Dijon, France
- Grenoble - CHU, Grenoble, France
- Centre Hospitalier - Pneumologie, Le Havre, France
- Centre Hospitalier - Pneumologie, Le Mans, France
- CHRU Lille - Hopital Calmette, Lille, France
- AP-HM Hôpital Nord, Marseille, France
- Mulhouse - CH, Mulhouse, France
- AP-HP Hopital Tenon - Pneumologie, Paris, France
- AP-HP Hôpital Bichat, Paris, France
- HCL Lyon Sud, Pierre-Bénite, France
- Pontoise - CH, Pontoise, France
- Rennes - CHU, Rennes, France
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02716272 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT07443020Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University